Stem Cell Market Research Reports & Industry Analysis
Cells must meet very specific criteria in order to be termed stem cells. They must: produce copies themselves; proliferate at a rapid rate; and display certain proteins on their surface that indicate a capacity to differentiate into other tissues, such as bone and cartilage. A stem cell line is a group of cells that all descend from a single original stem cell. Symmetric division gives rise to two identical daughter cells both endowed with stem cell properties. Asymmetric division produces only one stem cell and a progenitor cell with limited self-renewal potential.
Stem Cell Industry Research & Market Reports
-
Umbilical Cord Blood Banking
... 2030, growing at a CAGR of 10.1% over the analysis period 2024-2030. Public Cord Blood Banks, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$4.3 Billion ... Read More
-
Humanized Mouse and Rat Model
... Million by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$74.5 Million by ... Read More
-
CAR T-cell Therapy
... at a CAGR of 22.0% over the analysis period 2024-2030. DLBCL, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$5.1 Billion by the end of the ... Read More
-
Adult Stem Cells
... at a CAGR of 10.9% over the analysis period 2024-2030. Autologous Adult Stem Cells, one of the segments analyzed in the report, is expected to record a 12.4% CAGR and reach US$18.3 Billion by the ... Read More
-
Biopreservation
... 8.0% over the analysis period 2024-2030. Biopreservation Media, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth ... Read More
-
Human Embryonic Stem Cell (hESC) Research
... reach US$1.4 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Regenerative Medicine, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach ... Read More
-
Stem Cell Cartilage Regeneration
... 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Hematopoietic Stem Cells, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$507.8 Million by ... Read More
-
Allogeneic Stem Cells
... at a CAGR of 10.9% over the analysis period 2024-2030. Regenerative Therapy, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.6 Billion by the end of ... Read More
-
Viral Vector Manufacturing
... at a CAGR of 18.3% over the analysis period 2024-2030. Retroviral Vectors, one of the segments analyzed in the report, is expected to record a 18.1% CAGR and reach US$954.6 Million by the end of ... Read More
-
Stem Cell Banking
... at a CAGR of 7.5% over the analysis period 2024-2030. Placental and Cord Blood Stem Cells, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$10.5 Billion ... Read More
-
Induced Pluripotent Stem Cell (iPSC)
... Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Vascular Cells, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$1.1 Billion ... Read More
-
Human Organoids
... CAGR of 15.4% over the analysis period 2024-2030. Kidney, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$1.6 Billion by the end of the analysis period. ... Read More
-
Primary Immunodeficiency Therapeutics
... at a CAGR of 6.4% over the analysis period 2024-2030. Antibody Deficiency, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$8.5 Billion by the end of ... Read More
-
Cord Blood Banking Services
... 2030, growing at a CAGR of 10.1% over the analysis period 2024-2030. Private, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$79.3 Billion by the end ... Read More
-
Stem Cell Assays
... at a CAGR of 17.9% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 18.4% CAGR and reach US$6.1 Billion by the end of the ... Read More
-
Cell Viability Assays
... at a CAGR of 7.1% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$5.3 Billion by the end of the ... Read More
-
Canine Stem Cell Therapy
... 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Allogeneic Stem Cells, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$174.8 Million by ... Read More
-
Stem Cell Services
... at a CAGR of 9.8% over the analysis period 2024-2030. The U.S. Market is Estimated at US$8.3 Billion While China is Forecast to Grow at 9.0% CAGR The Stem Cell Services market in the U.S. ... Read More
-
Exosomes
... 14.6% over the analysis period 2024-2030. Cancer, one of the segments analyzed in the report, is expected to record a 16.5% CAGR and reach US$921.6 Million by the end of the analysis period. Growth in ... Read More
-
Hematopoietic Stem Cell Transplantation
... 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Allogenic Transplant Therapy Type, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$2.6 Billion ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
GMP Cell Banking Services
... 2030, growing at a CAGR of 15.0% over the analysis period 2024-2030. Biopharmaceutical Companies, one of the segments analyzed in the report, is expected to record a 14.6% CAGR and reach US$1.5 Billion by the ... Read More
-
Cell Banking Outsourcing
... at a CAGR of 16.1% over the analysis period 2024-2030. Master Cell Banking, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$19.7 Billion by the end ... Read More
-
Mesenchymal Stem Cells (MSC)
... 2030, growing at a CAGR of 12.2% over the analysis period 2024-2030. Bone Marrow, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$3.4 Billion by the ... Read More
-
ADME-Toxicology Testing
... CAGR of 11.2% over the analysis period 2024-2030. Cell Culture, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$9.6 Billion by the end of the analysis ... Read More
Research Assistance
